Pd66-05 safety, Feasibility, and Accuracy of the Uromonitor: A Catheter-Free Wireless Ambulatory Cystometry Device

Abstract

remaining OAB patients, N[87). Omnibus F-tests showed the groups differed on a number of variables including AUA-SI, ICIQ, UDI, IIQ, and GUPI, with C having worse symptoms than A & B.CONCLUSIONS: Our results demonstrate that latent class trajectory models of urge ratings during natural bladder filling reveals subtypes of OAB differing in clinical symptoms. Further analyses on rs-fMRI may reveal differences in pathophysiology between the three groups.

This Month in Adult Urology

“…Finally, Frainey et al (page 186) from Cleveland, Ohio, provide a manuscript describing a well-designed proof-of-concept study evaluating a device capable of providing a catheter-free, ambulatory, urodynamic assessment. 3 In a small group of patients, the authors show that the device was well tolerated, does not impede lower urinary tract function, and can reliably identify bladder events compared to urodynamics. The device shows promise to be able to study bladder function in less artificial, more routine clinical settings that we have previously not been able to effectively evaluate.…”

“…The authors conclude that the device could represent a simple solution to a common clinical problem, saving a great deal of patient morbidity and costs.Finally, Frainey et al (page 186) from Cleveland, Ohio, provide a manuscript describing a well-designed proof-of-concept study evaluating a device capable of providing a catheter-free, ambulatory, urodynamic assessment. 3 In a small group of patients, the authors show that the device was well tolerated, does not impede…”

Catheter-Free Urodynamics Testing: Current Insights and Clinical Potential

“…The device can remain in the bladder for up to seven days in the home setting and record bladder pressure. 20 When produced with a voiding diary, uroflowmetry, and the ability to record other physiological data, the UroMonitor will provide the most comprehensive UDS available to clinicians. A Phase II Small Business Innovation Research Proposal project has started in 2023 and will continue to 2025, with the primary objectives of developing the UroMonitor and evaluating the safety and feasibility of this device in a Clinical Feasibility Study and then bringing this device to market.…”

Editorial Comment

“…2,3 In this article, Frainey et al present their first evidence for the feasibility and safety of use of an insertable device (UroMonitor [UM]) that is capable of measuring bladder pressure and communicating the values wirelessly to a PC. 4 This was the natural step of development of UM following their presentation of technical details of UM in other biomedical journals. The authors ought to be congratulated for their scientific persistence.…”